DAIICHI SANKYO, INC.
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- Subsidiary
- Established
- 2010-01-01
- Employees
- 10K
- Market Cap
- $79B
- Website
- http://daiichisankyo.us
Long-Term Study of Safety and Efficacy of WelChol® as an Additional Therapy in Patients With Type 2 Diabetes
Phase 3
Completed
- Conditions
- Type 2 Diabetes
- First Posted Date
- 2005-09-09
- Last Posted Date
- 2008-01-09
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 780
- Registration Number
- NCT00151762
Olmesartan Pediatric Pharmacokinetic (PK) Study
- First Posted Date
- 2005-09-09
- Last Posted Date
- 2010-04-15
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 24
- Registration Number
- NCT00151814
Effects of Colesevelam on How the Body Responds to Insulin in Patients With Type 2 Diabetes
Phase 2
Completed
- Conditions
- Type 2 Diabetes
- Interventions
- First Posted Date
- 2005-09-07
- Last Posted Date
- 2014-04-02
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 36
- Registration Number
- NCT00147745
- Locations
- 🇺🇸
San Diego VMC, San Diego, California, United States
WelChol® and Sulfonylurea in Treating Patients With Type 2 Diabetes
Phase 3
Completed
- Conditions
- Type 2 Diabetes
- First Posted Date
- 2005-09-07
- Last Posted Date
- 2012-01-18
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 400
- Registration Number
- NCT00147758
WelChol® With Metformin in Treating Patients With Type 2 Diabetes
Phase 3
Completed
- Conditions
- Type 2 Diabetes
- First Posted Date
- 2005-09-07
- Last Posted Date
- 2012-01-18
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 300
- Registration Number
- NCT00147719
- Locations
- 🇺🇸
CRO, Jonesboro, Arkansas, United States
Efficacy and Safety of Colesevelam in Pediatric Patients With Genetic High Cholesterol
- First Posted Date
- 2005-09-05
- Last Posted Date
- 2010-04-15
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 194
- Registration Number
- NCT00145574
Placebo and Active Controlled Study of Rivoglitazone in Type 2 Diabetes
Phase 2
Completed
- Conditions
- Type 2 Diabetes
- First Posted Date
- 2005-09-02
- Last Posted Date
- 2021-05-10
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 441
- Registration Number
- NCT00143520
Study of the Efficacy and Safety of DU-176b in Preventing Blood Clots in Patients Undergoing Total Hip Replacement
- First Posted Date
- 2005-04-12
- Last Posted Date
- 2019-02-26
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 606
- Registration Number
- NCT00107900
- Locations
- 🇺🇸
Local Institution, Decatur, Georgia, United States
DX-8951f in Treating Patients With Metastatic Cancer of the Pancreas
Phase 2
Completed
- Conditions
- Pancreatic Cancer
- First Posted Date
- 2004-08-18
- Last Posted Date
- 2012-05-16
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 37
- Registration Number
- NCT00003951
- Locations
- 🇺🇸
Johns Hopkins Oncology Center, Baltimore, Maryland, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States
Chemotherapy in Treating Patients With Recurrent, Metastatic, or Unresectable Ovarian, Fallopian Tube, or Peritoneal Cancer
Phase 2
Completed
- Conditions
- Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cavity Cancer
- First Posted Date
- 2004-07-19
- Last Posted Date
- 2012-05-16
- Lead Sponsor
- Daiichi Sankyo
- Registration Number
- NCT00004060
- Locations
- 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States